Here’s a summary of the content to 2000 words, structured into six paragraphs in English:
—
### Q1 2025 Performance of Bayer’s Pharmaceutical Division: AGlanced at
Bayer, the world’s leading pharmaceutical giant, experienced a significant jump in its shares on the London Stock Exchange with a 10.5% surge on Tuesday morning. The company’s growth in the first quarter of 2025, driven by rising demand for its new cancer and kidney drugs, contributed to heightened stock valuations.
The company reported EBITDA for Q1 2025 of €4.1 billion, a 7.4% decline from the corresponding quarter a year ago. While still above market expectations of €3.9 billion, this decline reflects a poised strengthen in production and market presence.
The group’s sales reached €13.7 billion, a 0.1% decrease from the same quarter in 2024, underscoring the potential for sustained growth through expansion in key markets. Core earnings per share surged 11.7% to €2.5, driven by an improved operational efficiency despite interim declines.
Bayer’s Chief Executive Officer (CEO), Bill Anderson, remained optimistic, highlighting that the company’s ability to maximize its profits with limited resources is a strong indicator of competent decision-making. He emphasized confidence in the company’s fundamentals and the potential for continued innovation.
In the pharmaceuticals division, Bayer saw a robust growth in two specific sectors—prostate cancer treatment (Nubeqa) and chronic kidney disease treatment (Kerendia). Both products contributed significantly to sales in Q1 2025, partly due to the company’s recent advancements in these areas.
However, the anticoagulant Xareltoℎ’s sales remained down 4.1% in the quarter compared to the previous year, partly due to mat commercial expiration and slower glyphosate expansion. Despite this, the company’s crop-science segment reported a decline, driven by declining demand but with potential optimizations under way.
Bayer also monitored economic and geopolitical developments, which had a mixed reception. The company’s annual outlook for Q2 2025 was reaffirmed at around the 125-129% mark. This flexibility supported long-term growth.
In the crop-science segment, the company saw a decline of 4.1% in Q1 2025, partly due to slower demand from pesticide use and glyphosate expansion. The company may consider exiting the production of glyphosate in Louisiana as China intensifies its competition in the region.
The company has also taken note of pending litigation related to its stock-containing products, which could impact its profitability but also strengthen its reputation as a responsible business.
—
This summary captures the key aspects of Bayer’s performance for Q1 2025, highlighting growth in specific markets, financial results, and strategic considerations.
